Form 4: PharmaCyte Biotech Director Acquires Stock Options

PharmaCyte Biotech, Inc. director Wayne Remell Walker reports the acquisition of stock options.

Summary

• Wayne Remell Walker, a Director at PharmaCyte Biotech, Inc., has acquired stock options.
• The transaction occurred on March 31, 2026, with the options having an exercise price of $0.67.
• A total of 119,170 stock options were acquired.
• These options are exercisable for common stock and have an expiration date of March 30, 2036.
• The options are set to vest in full on the date of the Issuer's next annual meeting of stockholders, contingent upon Mr. Walker's continued service.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it represents a standard director compensation mechanism. The acquisition of options by a director can be seen as a positive signal of commitment, but it does not inherently guarantee future stock performance.

Positives

• Director acquisition of stock options can signal confidence in the company's future prospects.
• The exercise price of $0.67 suggests a potential for significant upside if the stock price increases.
• The large number of options acquired (119,170) indicates a substantial commitment by the director.

Risks

• The value of the stock options is entirely dependent on the future performance of PharmaCyte Biotech's stock price.
• Vesting is contingent on continued service, meaning the options could be forfeited if the director leaves the company before the vesting date.

Future Outlook

The future outlook for the stock options is tied to the company's performance and stock price appreciation, with full vesting contingent on continued service until the next annual meeting.

Management Comments

• The options shall vest in full on the date of the Issuer's next annual meeting of stockholders, subject to the continued service of Mr. Walker.

Industry Context

StockSavvy.ai notes that director stock option grants are a common form of executive compensation and incentive, aligning management's interests with those of shareholders. The specifics of this grant, including the exercise price and vesting schedule, will be crucial in assessing its potential impact on shareholder value.

Stakeholder Impact

• Shareholders: The grant of options to a director is a standard practice, but its ultimate impact depends on the company's future stock performance. If the stock price rises, it could dilute existing shares upon exercise, but also indicates management confidence.
• Employees: This filing does not directly impact employees, but the company's overall performance, influenced by management incentives, affects them.
• Management: The director receives potential future financial benefit tied to the company's stock performance.

Next Steps

• Mr. Walker's continued service until the next annual meeting of stockholders for options to vest.
• Potential exercise of stock options if the stock price exceeds the $0.67 exercise price before March 30, 2036.

Key Dates

Keywords

PharmaCyte Biotech, PMCB, Form 4, Stock Options, Director, Beneficial Ownership, SEC Filing, Securities Exchange Act